ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

The Hailie Smartinhaler device has also been cleared for use with inhalers from other manufacturers ... directly to patients with asthma and COPD under a 510(k) over-the-counter clearance.

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

However, by considering patients' individual circumstances and taking the time to ensure that they use the appropriate inhaler and technique, everyone can benefit. Asthma and COPD have a huge ...

Certain medications commonly used to treat asthma and COPD can damage the environment and worsen respiratory issues. KYW ...

Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple ...

Discover why doctors warn against vaping for people with these five health conditions including asthma, heart disease, and ...

In Chicago public schools that adopted a stock inhaler program, more students who used a stock inhaler for asthma symptoms ...

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...